Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma

Virology Journal

Volumn 10, Issue , 2013, Pages

  Sides, Mark D ^a   Sosulski, Meredith L ^a   Luo, Fayong ^a   Lin, Zhen ^a   Flemington, Erik K ^a   Lasky, Joseph A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arsenic trioxide; CNE1; Epstein Barr virus; Ganciclovir; Nasopharyngeal carcinoma; Promyelocytic leukemia nuclear bodies; Xenograft

Indexed keywords

ARSENIC TRIOXIDE; GANCICLOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; EPSTEIN BARR VIRUS; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; ARSENICALS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GANCICLOVIR; HETEROGRAFTS; HUMANS; MICE; NASOPHARYNGEAL NEOPLASMS; OXIDES; TREATMENT OUTCOME; TUMOR BURDEN;

HUMAN HERPESVIRUS 4; MURINAE;

EID: 84878376672     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-152     Document Type: Article

References (37)

1. Epidemiology of nasopharyngeal carcinoma. Yu MC, Yuan JM, Semin Cancer Biol 2002 12 421 429 10.1016/S1044579X02000858 12450728 (Pubitemid 35370755)
2. Nasopharyngeal carcinoma. Wei WI, Sham JS, Lancet 2005 365 2041 2054 10.1016/S0140-6736(05)66698-6 15950718 (Pubitemid 40812341)
3. Short-term effect of different teaching methods on nasopharyngeal carcinoma for general practitioners in Jakarta, Indonesia. Wildeman MA, Fles R, Adham M, Mayangsari ID, Luirink I, Sandberg M, Vincent AD, Fardizza F, Musa Z, Armiyanto, PLoS One 2012 7 32756 10.1371/journal.pone.0032756 22431981
4. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
5. DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma. Nonoyama M, Huang CH, Pagano JS, Klein G, Singh S, Proc Natl Acad Sci USA 1973 70 3265 3268 10.1073/pnas.70.11.3265 4361687
6. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Tao Q, Chan AT, Expert Rev Mol Med 2007 9 1 24 18088444 (Pubitemid 47398642)
7. EB viral genomes in epithelial nasopharyngeal carcinoma cells. Wolf H, Zur Hausen H, Becker V, Nat New Biol 1973 244 245 247 4353684
8. Association of Epstein-Barr virus with nasopharyngeal carcinoma and current status of development of cancer-derived cell lines. Gullo C, Low WK, Teoh G, Ann Acad Med Singapore 2008 37 769 777 18989494
9. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L, Nature 1970 228 1056 1058 10.1038/2281056a0 4320657
10. Further evidence for the existence of major susceptibility of nasopharyngeal carcinoma in the region near HLA-A locus in Southern Chinese. Zhao M, Cai H, Li X, Zheng H, Yang X, Fang W, Zhang L, Wei G, Li M, Yao K, J Transl Med 2012 10 57 10.1186/1479-5876-10-57 22440091
11. Association of cyclin D1 genotypes with nasopharyngeal carcinoma risk. Shih LC, Tsai CW, Tsai MH, Tsou YA, Chang WS, Li FJ, Lee MH, Bau DT, Anticancer Res 2012 32 1093 1098 22399638
12. Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. Murata M, Thanan R, Ma N, Kawanishi S, J Biomed Biotechnol 2012 2012 623019 22363173
13. Familial and large-scale case-control studies identify genes associated with nasopharyngeal carcinoma. Bei JX, Jia WH, Zeng YX, Semin Cancer Biol 2012 22 96 106 10.1016/j.semcancer.2012.01.012 22313875
14. Non-viral environmental risk factors for nasopharyngeal carcinoma: a systematic review. Jia WH, Qin HD, Semin Cancer Biol 2012 22 117 126 10.1016/j.semcancer.2012.01.009 22311401
15. Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011: Rosetta Stone for NPC: genetics, viral infection, and other environmental factors. Hildesheim A, Wang CP, Semin Cancer Biol 2012 22 107 116 10.1016/j.semcancer.2012.01.007 22300735
16. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. Jia WH, Huang QH, Liao J, Ye W, Shugart YY, Liu Q, Chen LZ, Li YH, Lin X, Wen FL, BMC Cancer 2006 6 178 10.1186/1471-2407-6-178 16822324 (Pubitemid 44308903)
17. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, Tan IB, Middeldorp JM, Chin J Cancer 2012 31 185 196 10.5732/cjc.011.10328 22313595
18. Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo. Daibata M, Bandobashi K, Kuroda M, Imai S, Miyoshi I, Taguchi H, J Virol 2005 79 5875 5879 10.1128/JVI.79.9.5875-5879.2005 15827204 (Pubitemid 40548258)
19. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, Raab-Traub N, Delecluse HJ, Kenney SC, J Natl Cancer Inst 2004 96 1691 1702 10.1093/jnci/djh313 15547182 (Pubitemid 39585638)
20. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. Feng WH, Hong G, Delecluse HJ, Kenney SC, J Virol 2004 78 1893 1902 10.1128/JVI.78.4.1893-1902.2004 14747554 (Pubitemid 38176721)
21. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Feng WH, Kenney SC, Cancer Res 2006 66 8762 8769 10.1158/0008-5472.CAN-06-1006 16951192 (Pubitemid 44449193)
22. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Hui KF, Chiang AK, Int J Cancer 2010 126 2479 2489 19816947
23. Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir. Jung EJ, Lee YM, Lee BL, Chang MS, Kim WH, Cancer Lett 2007 247 77 83 10.1016/j.canlet.2006.03.022 16647201 (Pubitemid 44959412)
24. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF, Antimicrob Agents Chemother 2001 45 2082 2091 10.1128/AAC.45.7.2082-2091.2001 11408227 (Pubitemid 32591702)
25. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC, Cancer Res 2000 60 5781 5788 11059774
26. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC, J Virol 2010 84 4534 4542 10.1128/JVI.02487-09 20181711
27. Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells. Sides MD, Block GJ, Shan B, Esteves KC, Lin Z, Flemington EK, Lasky JA, Virology 2011 416 86 97 10.1016/j.virol.2011.04.005 21605886
28. Inhibition of growth of human nasopharyngeal cancer xenografts in SCID mice by arsenic trioxide. Li D, Du C, Lin Y, Wu M, Tumori 2002 88 522 526 12597150 (Pubitemid 36193904)
29. Differentiation of human nasopharyngeal carcinoma xenografts and repression of telomerase activity induced by arsenic trioxide. Du C, Li D, Lin Y, Wu M, Natl Med J India 2004 17 67 70 15141597 (Pubitemid 38578962)
30. Synergistic therapeutic effect of arsenic trioxide and radiotherapy in BALB/C nude mice bearing nasopharyngeal carcinoma xenografts. Xie LX, Lin XH, Li DR, Chen JY, Hong CQ, Du CW, Exp Oncol 2007 29 45 48 17431388 (Pubitemid 46713479)
31. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lin CT, Chan WY, Chen W, Huang HM, Wu HC, Hsu MM, Chuang SM, Wang CC, Lab Invest 1993 68 716 727 7685844
32. Tumor growth inhibition of metastatic nasopharyngeal carcinoma cell lines by low dose of arsenic trioxide via alteration of cell cycle progression and induction of apoptosis. Yeh KY, Chang JW, Li YY, Wang CH, Wang HM, Head Neck 2011 33 734 742 10.1002/hed.21535 20737493
33. Arsenic trioxide reduces the invasive and metastatic properties of nasopharyngeal carcinoma cells in vitro. Du CW, Wen BG, Li DR, Peng X, Hong CQ, Chen JY, Lin ZZ, Hong X, Lin YC, Xie LX, Braz J Med Biol Res 2006 39 677 685 10.1590/S0100-879X2006000500015 16648906 (Pubitemid 43676618)
34. Latent membrane protein-1 of Epstein-Barr virus increases sensitivity to arsenic trioxide-induced apoptosis in nasopharyngeal carcinoma cell. Du CW, Wen BG, Li DR, Lin YC, Zheng YW, Chen L, Chen JY, Lin W, Wu MY, Exp Oncol 2005 27 267 272 16404345 (Pubitemid 43139356)
35. [Arsenic trioxide induces differentiation of human nasopharyngeal carcinoma in BALB/C nude mice xenograft model]. Du CW, Li DR, Lin YC, Wu MY, Ai Zheng 2003 22 21 25 12561430
36. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl- methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Neyts J, Sadler R, De Clercq E, Raab-Traub N, Pagano JS, Cancer Res 1998 58 384 388 9458076 (Pubitemid 28087393)
37. Cytolytic Virus Activation Therapy for Epstein-Barr Virus Driven Tumours. Wildeman MA, Novalic Z, Verkuijlen SA, Juwana H, Huitema AD, Tan IB, Middeldorp JM, De Boer JP, Greijer AE, Clin Cancer Res 2012 Sept 15 18 18 5061 70 10.1158/1078-0432.CCR-12-0574